BioSpace News Archive

While the space is just beginning to emerge, therapies for long-haul COVID-19 patients are still very much an unmet need.

Lonza has been in the process of separating LSI into a standalone unit since 2019.

Ever since Dr. Fauci said he often double masks and that two masks “just makes common sense,” the medical community has been in somewhat of a debate with many in agreement, and some saying the opposite.

The choice for the new FDA commissioner will tell the public about the Biden administration’s battle plan with regards to handling the global pandemic.

The cash just keeps coming for biopharma companies. Here’s a rundown of some of this week’s investment dollar recipients.

Hepion Pharmaceuticals, Inc. a clinical stage biopharmaceutical company focused on Artificial Intelligence driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis and liver disease, announced today that management will participate in the BIO CEO & Investor Digital Conference, which is being held February 16 - 18, 2021.

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced two supply agreements for the COVID-19 Vaccine Moderna: one with the government of Taiwan for 5 million doses and another with the government of Colombia for 10 million doses. Under the terms of the agreements, deliveries would begin in mid-2021.

Vigil Health Solutions Inc. (“Vigil”) announces the results of operations for the quarter ending December 31, 2020. Developments in the Quarter Revenue of $1.76 million compared to $1.01 million in the three month period ended December 31, 2019.

Insightec®, a global healthcare company focused on creating the next generation of patient care, announced it received market approval by The National Medical Products Administration (NMPA), the Chinese agency for regulating drugs and medical devices (formerly the China Food and Drug Administration, or CFDA).

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the pricing of an underwritten public offering in the United States of 14,285,715 American Depositary Shares (“ADSs”) representing 14,285,715 ordinary shares at a public offering price of $7.00 per ADS, for total gross proceeds of approximately $100.0 million